A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Trial Profile

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Lymphoma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms Study 10
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 23 Mar 2018 Accoprding to a Clovis Oncology media release, formal approval from the European Commission is anticipated in second quarter 2018.
    • 23 Mar 2018 Accoprding to a Clovis Oncology media release, CHMP adopted a positive opinion recommending the granting of a conditional marketing authorisation for rucaparib as a monotherapy for adult patients with platinum sensitive, relapsed or progressive, BRCA-mutant high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.
    • 21 Feb 2018 According to a Clovis Oncology media release, based on data from two studies (Study 10 and ARIEL2), the CHMP application was submitted during the fourth quarter of 2016 and is currently under review.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top